Lycia Therapeutics develops LYTAC degraders that target and eliminate disease-causing proteins, particularly those involved in autoimmune and inflammatory diseases. This technology addresses the issue of dysregulated proteins that contribute to various diseases, offering a customizable approach to therapeutics that can potentially treat previously undruggable targets.
Funding
$261.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are caused by dysregulated proteins circulating in the blood or attached to the outside of cells. These proteins, including some previously considered "undruggable," drive autoimmune and inflammatory diseases. Current therapeutic options often fail to address the root cause of these diseases.
Solution
Lycia Therapeutics develops LYTAC (LYsosome-Targeting Chimera) degraders, a novel class of therapeutics designed to selectively eliminate disease-causing extracellular proteins. The LYTAC platform is modular and customizable, enabling the creation of therapeutics that target and degrade specific pathogenic proteins. By reducing the levels of these proteins, Lycia aims to stop disease at its source and offer new treatment options for a broad spectrum of diseases, initially focusing on autoimmune and inflammatory conditions.
Target Audience
The primary target audience includes patients suffering from autoimmune and inflammatory diseases, as well as pharmaceutical companies seeking innovative therapeutic approaches for previously untreatable conditions.
Features
- LYTAC degraders target and eliminate specific extracellular proteins.
- Modular platform allows customization to address diverse disease targets.
- Designed to degrade proteins previously considered undruggable.
- Potential application across a broad spectrum of diseases.